A Comparison between Sodium Valproate and Fluoxetine in Patients with Migraine Headaches and Chronic Fatigue Syndrome

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Neurology AND Isfahan Neuroscience Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Neurology AND Isfahan Neuroscience Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Migraine is one of the most common causes of headache characterize by pulsatile headache. Most patients with migraine experience chronic fatigue syndrome. This syndrome includes chronic fatigue for at least 6 months with neurological symptoms and muscular pain. One of the first line agents in migraine treatment is sodium valproate. In addition, usage of fluoxetine as a prophylactic treatment of migraine has been effective in recent researches. In this research, a comparison between sodium valproate and fluoxetine in treatment of patients with migraine and chronic fatigue syndrome was done.Methods: In this clinical trial study, 64 patients with migraine and chronic fatigue syndrome were enrolled. They were divided into two equal groups of 32 participants. Each group took one of the fluoxetine (20 mg daily) or sodium valproate (400 mg daily) for 8 weeks. The groups were compared in aspect of intensity score and frequency of headaches. Student's t and ANOVA statistical tests were used to analysis the results.Findings: The mean headache intensity score decreased in both sodium valproate and fluoxetine groups by 34.83% and 22.82%, respectively. In addition, the mean headache frequency decreased in both fluoxetine and sodium valproate groups by 23.68% and 40.54%, respectively.Conclusion: It could be understood that both sodium valproate and fluoxetine are effective in treatment of migraine with history of chronic fatigue syndrome, yet sodium valproate was more effective. The effectiveness of fluoxetine was obvious in patients with depression history.

Keywords

References

  1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41(7): 646-57.
  2. Cutrer FM. Pathophysiology of migraine. Semin Neurol 2010; 30(2): 120-30.
  3. Bajwa ZH, Sabahat A. Acute treatment of migraine in adults. UpToDate 2013 [Online]. [cited 2013 Jan 10]; Available from: URL:
  4. http://iranuptodate.ir/contents/mobipreview.htm?20/44/21194?source=see_link
  5. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71(8): 559-66.
  6. Evengard B, Klimas N. Chronic fatigue syndrome: probable pathogenesis and possible treatments. Drugs 2002; 62(17): 2433-46.
  7. Gilje AM, Soderlund A, Malterud K. Obstructions for quality care experienced by patients with chronic fatigue syndrome (CFS)--a case study. Patient Educ Couns 2008; 73(1): 36-41.
  8. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160(2): 221-36.
  9. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160(2): 221-7.
  10. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med 1999; 159(18): 2129-37.
  11. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55(6): 754-62.
  12. d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39(10): 716-9.
  13. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919.
  14. Koch HJ, Jurgens TP. Antidepressants in long-term migraine prevention. Drugs 2009; 69(1): 1-19.
  15. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58(11): 1652-9.
  16. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7(1): 51-4.
  17. Friedberg F, Jason LA. Chronic fatigue syndrome and fibromyalgia: clinical assessment and treatment. J Clin Psychol 2001; 57(4): 433-55.
  18. Rimes KA, Chalder T. Treatments for chronic fatigue syndrome. Occup Med (Lond) 2005; 55(1): 32-9.
  19. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory--Second edition: BDI-II-PERSIAN. Depress Anxiety 2005; 21(4): 185-92.
  20. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27(11): 1293-300.
  21. Finocchi C, Villani V, Casucci G. Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence. Neurol Sci 2010; 31(Suppl 1): S95-S98.
Journal of Isfahan Medical School
Volume 34, Issue 407 - Serial Number 407
September and October 2017
Pages 1369-1374

Files

History

  • Receive Date: 24 August 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics